OpGen Stock Price, News & Analysis (NASDAQ:OPGN)

$1.97 -0.08 (-3.90 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$2.05
Today's Range$1.89 - $2.14
52-Week Range$1.85 - $31.25
Volume267,032 shs
Average Volume507,935 shs
Market Capitalization$9.99 million
P/E RatioN/A
Dividend YieldN/A
Beta0.71

About OpGen (NASDAQ:OPGN)

OpGen logoOpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.

Receive OPGN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPGN
CUSIPN/A
Phone240-813-1260

Debt

Debt-to-Equity Ratio0.03%
Current Ratio1.23%
Quick Ratio1.13%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.03 million
Price / Sales2.41
Cash FlowN/A
Price / CashN/A
Book Value$3.64 per share
Price / Book0.54

Profitability

Trailing EPS($15.50)
Net Income$-19,160,000.00
Net Margins-533.47%
Return on Equity-1,289.51%
Return on Assets-234.78%

Miscellaneous

Employees62
Outstanding Shares4,920,000

OpGen (NASDAQ:OPGN) Frequently Asked Questions

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

When did OpGen's stock split? How did OpGen's stock split work?

OpGen's stock reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

How were OpGen's earnings last quarter?

OpGen Inc (NASDAQ:OPGN) issued its quarterly earnings results on Thursday, May, 12th. The medical research company reported ($9.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($7.50) by $1.50. The medical research company had revenue of $1.10 million for the quarter. OpGen had a negative net margin of 533.47% and a negative return on equity of 1,289.51%. View OpGen's Earnings History.

When will OpGen make its next earnings announcement?

OpGen is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for OpGen.

Where is OpGen's stock going? Where will OpGen's stock price be in 2018?

2 brokers have issued 12-month price targets for OpGen's stock. Their forecasts range from $9.00 to $9.00. On average, they expect OpGen's share price to reach $9.00 in the next year. View Analyst Ratings for OpGen.

What are Wall Street analysts saying about OpGen stock?

Here are some recent quotes from research analysts about OpGen stock:

  • 1. According to Zacks Investment Research, "OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. " (2/16/2018)
  • 2. HC Wainwright analysts commented, "We note that these results reflect the company’s ongoing efforts to reduce operating expenses. Of note, management expects a further decline in operating expenses by 25-30% in 2H 2017, as compared to 1H 2017. OpGen is in the process of consolidating its manufacturing footprint and prioritizing R&D spending to develop the Acuitas rapid test. Management indicated that the company would make efforts to maintain gross margins within the historical range of 40-60%, which would be a healthy level, in our view. Evidently, the company aims to be capital efficient, which may boost shareholder value in the near term." (8/9/2017)

Who are some of OpGen's key competitors?

Who are OpGen's key executives?

OpGen's management team includes the folowing people:

  • Evan Jones, Chairman of the Board, Chief Executive Officer (Age 60)
  • Timothy C. Dec, Chief Financial Officer, Corporate Secretary (Age 58)
  • Geoffrey A. McKinley Ph.D., Senior Vice President - Research and Development and Business Development (Age 65)
  • G. Terrance Walker Ph.D., Senior Vice President - Research and Development (Age 58)
  • Vadim Sapiro, Chief Information Officer (Age 46)
  • Robert McG. Lilley, Chief Commercial Officer (Age 71)
  • Brian G. Atwood, Independent Director (Age 64)
  • Harry J. D'Andrea, Independent Director (Age 60)
  • Timothy J. R. Harris Ph.D., Independent Director (Age 66)
  • Tina Susan Nova Ph.D., Independent Director (Age 63)

When did OpGen IPO?

(OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

Who owns OpGen stock?

OpGen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (22.96%), SABBY MANAGEMENT, LLC (5.17%) and SABBY MANAGEMENT, LLC (5.17%). Company insiders that own OpGen stock include Jven Capital, Llc and Timothy C Dec. View Institutional Ownership Trends for OpGen.

Who sold OpGen stock? Who is selling OpGen stock?

OpGen's stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for OpGen.

How do I buy OpGen stock?

Shares of OpGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OpGen's stock price today?

One share of OpGen stock can currently be purchased for approximately $1.97.

How big of a company is OpGen?

OpGen has a market capitalization of $9.99 million and generates $4.03 million in revenue each year. The medical research company earns $-19,160,000.00 in net income (profit) each year or ($15.50) on an earnings per share basis. OpGen employs 62 workers across the globe.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]


MarketBeat Community Rating for OpGen (OPGN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  170
MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OpGen (NASDAQ:OPGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$25.00$25.00$25.00
Price Target Upside: 258.57% upside251.99% upside251.99% upside212.89% upside

OpGen (NASDAQ:OPGN) Consensus Price Target History

Price Target History for OpGen (NASDAQ:OPGN)

OpGen (NASDAQ:OPGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/7/2018HC WainwrightBoost Price TargetBuy -> Buy$9.00MediumView Rating Details
6/19/2017Dawson JamesReiterated RatingBuyLowView Rating Details
8/10/2016Rodman & RenshawSet Price TargetBuy$82.50N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

OpGen (NASDAQ:OPGN) Earnings History and Estimates Chart

Earnings by Quarter for OpGen (NASDAQ:OPGN)

OpGen (NASDAQ OPGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018($0.06)N/AView Earnings Details
11/7/2017Q3 2017($2.00)($1.75)$0.86 million$0.75 millionViewN/AView Earnings Details
8/8/2017Q2 2017($4.00)($3.75)$0.82 million$0.70 millionViewN/AView Earnings Details
4/26/2017Q1 2017($3.75)($4.75)$1.03 million$0.77 millionViewN/AView Earnings Details
3/23/2017Q4 2016($5.00)($5.25)$1.00 million$1.01 millionViewN/AView Earnings Details
10/24/2016Q3($6.75)($5.75)$1.10 million$0.73 millionViewListenView Earnings Details
8/9/2016Q2 2016($7.00)($9.25)$1.10 million$1.18 millionViewN/AView Earnings Details
5/12/2016Q1($7.50)($9.00)$1.10 millionViewListenView Earnings Details
3/30/2016Q4($9.50)$1.33 millionViewListenView Earnings Details
11/12/2015Q315($9.50)$0.98 millionViewListenView Earnings Details
8/13/2015Q215($21.00)$1.10 million$0.38 millionViewListenView Earnings Details
6/17/2015Q115($140.25)$0.47 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

OpGen (NASDAQ:OPGN) Earnings Estimates

Current Year EPS Consensus Estimate: $-10 EPS
Next Year EPS Consensus Estimate: $-2.31 EPS

Dividends

Dividend History for OpGen (NASDAQ:OPGN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

OpGen (NASDAQ OPGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.40%
Insider Trades by Quarter for OpGen (NASDAQ:OPGN)
Institutional Ownership by Quarter for OpGen (NASDAQ:OPGN)

OpGen (NASDAQ OPGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/18/2017Jven Capital, LlcChairmanBuy1,875,000$0.40$750,000.00View SEC Filing  
7/18/2017Timothy C DecCFOBuy65,000$0.40$26,000.00118,966View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

OpGen (NASDAQ OPGN) News Headlines

Source:
DateHeadline
OpGen (OPGN) Rating Lowered to Hold at Zacks Investment ResearchOpGen (OPGN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 16 at 6:46 AM
OpGen (OPGN) Raised to Buy at Zacks Investment ResearchOpGen (OPGN) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - February 15 at 6:26 AM
BRIEF-OpGen Says ‍Entered Agreement To Use Thermo Fishers Real-Time PCR Technology In Cos New Acuitas TestsBRIEF-OpGen Says ‍Entered Agreement To Use Thermo Fisher's Real-Time PCR Technology In Co's New Acuitas Tests
www.reuters.com - February 13 at 9:22 AM
OpGen Strengthens Supplier Relationship to Use Industry-Leading Real-Time PCR Technology for New Acuitas® TestsOpGen Strengthens Supplier Relationship to Use Industry-Leading Real-Time PCR Technology for New Acuitas® Tests
finance.yahoo.com - February 13 at 9:22 AM
OpGen Announces Closing of $12 Million Public OfferingOpGen Announces Closing of $12 Million Public Offering
finance.yahoo.com - February 7 at 8:58 AM
 Brokerages Anticipate OpGen Inc (OPGN) to Post -$1.38 Earnings Per Share Brokerages Anticipate OpGen Inc (OPGN) to Post -$1.38 Earnings Per Share
www.americanbankingnews.com - February 6 at 11:22 PM
OpGen regains Nasdaq compliance but Wall Street woes continueOpGen regains Nasdaq compliance but Wall Street woes continue
finance.yahoo.com - February 5 at 3:38 PM
OpGen Regains Compliance With Nasdaq Listing Requirements - GlobeNewswire (press release)OpGen Regains Compliance With Nasdaq Listing Requirements - GlobeNewswire (press release)
globenewswire.com - February 5 at 9:11 AM
OpGen Regains Compliance With Nasdaq Listing RequirementsOpGen Regains Compliance With Nasdaq Listing Requirements
finance.yahoo.com - February 5 at 9:11 AM
OpGen (OPGN) Upgraded to Sell by ValuEngineOpGen (OPGN) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - February 4 at 6:36 PM
OpGen Announces Pricing of $12 Million Upsized Public Offering - GlobeNewswire (press release)OpGen Announces Pricing of $12 Million Upsized Public Offering - GlobeNewswire (press release)
globenewswire.com - February 4 at 8:58 AM
OpGen (OPGN) Prices 3.7M Share Upsized Common Offering at $3.25/ShOpGen (OPGN) Prices 3.7M Share Upsized Common Offering at $3.25/Sh
www.streetinsider.com - February 2 at 8:52 AM
OpGen Introduces New RUO Rapid Test for Infection Control and Surveillance StudiesOpGen Introduces New RUO Rapid Test for Infection Control and Surveillance Studies
finance.yahoo.com - February 1 at 9:16 AM
Zacks: OpGen Inc (OPGN) Given Consensus Rating of "Strong Buy" by BrokeragesZacks: OpGen Inc (OPGN) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 27 at 9:14 PM
OpGen (OPGN) Cut to Strong Sell at ValuEngineOpGen (OPGN) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - January 25 at 6:58 PM
Is OpGen Inc’s (NASDAQ:OPGN) CEO Incentives Align With Yours?Is OpGen Inc’s (NASDAQ:OPGN) CEO Incentives Align With Yours?
finance.yahoo.com - January 25 at 9:05 AM
Zacks: Analysts Expect OpGen Inc (OPGN) Will Announce Quarterly Sales of $810,000.00Zacks: Analysts Expect OpGen Inc (OPGN) Will Announce Quarterly Sales of $810,000.00
www.americanbankingnews.com - January 23 at 1:48 PM
Brokerages Expect OpGen Inc (OPGN) to Post ($1.38) Earnings Per ShareBrokerages Expect OpGen Inc (OPGN) to Post ($1.38) Earnings Per Share
www.americanbankingnews.com - January 20 at 9:42 AM
OpGen shareholders approve reverse stock split in bid to avoid delistingOpGen shareholders approve reverse stock split in bid to avoid delisting
finance.yahoo.com - January 18 at 11:12 AM
OpGen Announces Execution of Reverse Stock SplitOpGen Announces Execution of Reverse Stock Split
finance.yahoo.com - January 17 at 4:42 PM
Heres what’s next for OpGen as it faces delisting threatHere's what’s next for OpGen as it faces delisting threat
finance.yahoo.com - January 11 at 4:45 PM
OpGen (OPGN) Downgraded by Zacks Investment ResearchOpGen (OPGN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 10 at 6:00 AM
OpGen (OPGN) and NewLink Genetics (NLNK) Head-To-Head SurveyOpGen (OPGN) and NewLink Genetics (NLNK) Head-To-Head Survey
www.americanbankingnews.com - January 9 at 1:10 AM
Zacks: Analysts Expect OpGen, Inc. (OPGN) Will Announce Quarterly Sales of $810,000.00Zacks: Analysts Expect OpGen, Inc. (OPGN) Will Announce Quarterly Sales of $810,000.00
www.americanbankingnews.com - January 6 at 5:48 AM
OpGen (OPGN) versus Its Competitors Head-To-Head AnalysisOpGen (OPGN) versus Its Competitors Head-To-Head Analysis
www.americanbankingnews.com - January 4 at 5:02 PM
OpGen (OPGN) vs. The Competition Financial SurveyOpGen (OPGN) vs. The Competition Financial Survey
www.americanbankingnews.com - January 3 at 3:12 AM
ETFs with exposure to OpGen, Inc. : January 2, 2018ETFs with exposure to OpGen, Inc. : January 2, 2018
finance.yahoo.com - January 2 at 5:31 PM
Contrasting OpGen (OPGN) and Its RivalsContrasting OpGen (OPGN) and Its Rivals
www.americanbankingnews.com - December 30 at 7:12 PM
Zacks: Analysts Set $1.50 Target Price for OpGen, Inc. (OPGN)Zacks: Analysts Set $1.50 Target Price for OpGen, Inc. (OPGN)
www.americanbankingnews.com - December 30 at 7:50 AM
Analyzing OpGen (OPGN) & Its PeersAnalyzing OpGen (OPGN) & Its Peers
www.americanbankingnews.com - December 28 at 11:40 AM
ETFs with exposure to OpGen, Inc. : December 22, 2017ETFs with exposure to OpGen, Inc. : December 22, 2017
finance.yahoo.com - December 22 at 7:37 PM
Financial Review: OpGen (OPGN) & Its PeersFinancial Review: OpGen (OPGN) & Its Peers
www.americanbankingnews.com - December 20 at 9:32 AM
ETFs with exposure to OpGen, Inc. : December 11, 2017ETFs with exposure to OpGen, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 4:48 PM
 OpGen, Inc. (OPGN) Given Consensus Recommendation of "Strong Buy" by Brokerages OpGen, Inc. (OPGN) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 10 at 9:58 PM
Head to Head Analysis: OpGen (OPGN) versus The CompetitionHead to Head Analysis: OpGen (OPGN) versus The Competition
www.americanbankingnews.com - December 9 at 1:22 AM
OpGen, Inc. (OPGN) Expected to Announce Quarterly Sales of $910,000.00OpGen, Inc. (OPGN) Expected to Announce Quarterly Sales of $910,000.00
www.americanbankingnews.com - December 2 at 6:54 AM
Should You Be Content With OpGen Inc’s (OPGN) 56.9% Earnings Growth?Should You Be Content With OpGen Inc’s (OPGN) 56.9% Earnings Growth?
finance.yahoo.com - November 30 at 4:37 PM
ETFs with exposure to OpGen, Inc. : November 30, 2017ETFs with exposure to OpGen, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 4:37 PM
 Brokerages Anticipate OpGen, Inc. (OPGN) Will Announce Earnings of -$0.06 Per Share Brokerages Anticipate OpGen, Inc. (OPGN) Will Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - November 30 at 1:46 PM
Zacks: OpGen, Inc. (OPGN) Given Average Rating of "Strong Buy" by AnalystsZacks: OpGen, Inc. (OPGN) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - November 30 at 1:28 AM
OpGen, Inc. :OPGN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017OpGen, Inc. :OPGN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:22 AM
What Falling Estimates & Price Mean for INC Research (INCR)What Falling Estimates & Price Mean for INC Research (INCR)
www.zacks.com - November 24 at 9:14 AM
OpGen (OPGN) and Compugen (CGEN) Head-To-Head AnalysisOpGen (OPGN) and Compugen (CGEN) Head-To-Head Analysis
www.americanbankingnews.com - November 22 at 3:18 AM
OpGen, Inc. (OPGN) Expected to Post Quarterly Sales of $910,000.00OpGen, Inc. (OPGN) Expected to Post Quarterly Sales of $910,000.00
www.americanbankingnews.com - November 14 at 2:14 PM
OpGen, Inc. (OPGN) Upgraded by Zacks Investment Research to BuyOpGen, Inc. (OPGN) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - November 14 at 6:30 AM
OpGen, Inc. (OPGN) Expected to Post Earnings of -$0.06 Per ShareOpGen, Inc. (OPGN) Expected to Post Earnings of -$0.06 Per Share
www.americanbankingnews.com - November 12 at 1:08 AM
OpGens (OPGN) CEO Evan Jones on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaOpGen's (OPGN) CEO Evan Jones on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 11 at 8:02 AM
OpGen, Inc. to Host Earnings CallOpGen, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 10:28 AM
Edited Transcript of OPGN earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of OPGN earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 10:28 AM
OpGens (OPGN) "Buy" Rating Reaffirmed at HC WainwrightOpGen's (OPGN) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 8 at 10:26 PM

SEC Filings

OpGen (NASDAQ:OPGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

OpGen (NASDAQ:OPGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

OpGen (NASDAQ OPGN) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.